GlassScriptPhysician profile
Megan Palmer
NPI 1023492709
$2,037.60
in general payments reported to CMS, 2019-2025
22 companies · $385 in 2025
The $385 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $277 · 2022: $521 · 2023: $389 · 2024: $465 · 2025: $385.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,240.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,239.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $323.69 | 2022-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $247.99 | 2022-2024 | Jornay Pm |
| Kaleo, INC. | $153.81 | 2021-2023 | Auvi-Q |
| Seqirus USA INC | $140.38 | 2022-2025 | Flucelvax, Fluad, Flucelvax Quadrivalent |
| Supernus Pharmaceuticals, INC. | $134.15 | 2021-2025 | Qelbree, Qelbree |
| Pfizer INC. | $125.38 | 2021-2025 | |
| Neos Therapeutics, LP | $108.54 | 2021-2023 | Cotempla Xr-Odt |
| Sobi, INC | $99.03 | 2022 | |
| Sanofi-Aventis U.S. LLC | $86.42 | 2024 | |
| Tris Pharma INC | $80.81 | 2021-2023 | Dyanavel Xr |
| Sanofi Pasteur INC. | $76.86 | 2022-2025 | |
| Adlon Therapeutics L.P. | $68.59 | 2021 | |
| Vertical Pharmaceuticals, LLC | $64.41 | 2024-2025 | Relexxii, Methylphenidate Hydrochloride |
| Collegium Pharmaceutical, INC. | $52.62 | 2025 | Jornay Pm |
| Novo Nordisk INC | $50.44 | 2023-2025 | Wegovy |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $48.47 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $40.81 | 2023-2025 | Vaxneuvance, Gardasil 9, Vaxelis |
| Cranial Technologies, INC | $36.43 | 2023-2024 | Doc Band |
| Teva Pharmaceuticals USA, INC. | $31.62 | 2021 | |
| Glaxosmithkline, LLC. | $30.04 | 2025 | Bexsero |
| Aytu Biopharma, INC. | $20.67 | 2024 | Karbinal |
| Noven Therapeutics, LLC | $16.44 | 2023 | Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Palmer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.